Speed of onset of bronchodilator response to salbutamol inhaled via different devices in asthmatics: A bioassay based on functional antagonism

British Journal of Clinical Pharmacology

Volumn 62, Issue 4, 2006, Pages 403-411

  Lavorini, Federico ^a   Geri, Pietro ^a   Mariani, Laura ^a   Marmai, Cecilia ^a   Maluccio, Nazzarena Maria ^a   Pistolesi, Massimo ^a   Fontana, Giovanni A ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Asthma; Dry powder inhaler; Functional antagonism; Spacers; Speed of bronchodilation

Indexed keywords

BRONCHODILATING AGENT; METHACHOLINE; PLACEBO; SALBUTAMOL;

ADULT; ARTICLE; ASTHMA; BIOASSAY; BRONCHODILATATION; BRONCHOSPASM; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG POTENCY; DRUG TARGETING; DRY POWDER; EXPIRATORY FLOW; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATION SPACER; INHALER; INTERMETHOD COMPARISON; LUNG; MALE; MEDICAL NEBULIZER; METERED DOSE INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ALBUTEROL; ASTHMA; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METERED DOSE INHALERS; VITAL CAPACITY;

EID: 33748744038     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02641.x     Document Type: Article

References (41)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Washington DC. National Institute of Health, National Heart, Lung and Blood Institute, 2002. Publication no. 02-3659.
2. Pauwels R, Lamont H, Hidinger K, Van Der Straeten M. Influence of an extension tube on the bronchodilator efficacy of terbutaline delivered from a metered dose inhaler. Respiration 1984; 45: 61-6.
3. Fontana GA, Lavorini F, Chiostri M, Castellani W, Boddi V, Pistolesi M. Large and small airway responses to procaterol hydrochloride administered through different extension devices in asthmatic patients. J Aerosol Med 1999; 12: 177-85.
4. Price AH, Clissold SP. Salbutamol in the 1980s. A reappraisal of its clinical efficacy. Drugs 1989; 38: 77-122.
5. Beach JR, Bromly CL, Avery AJ, Reid RW, Walters EH, Hendrick DJ. Speeds of action of single doses of formoterol and salbutamol compared with placebo in reversing methacholine-induced bronchoconstriction. Pulm Pharmacol 1996; 9: 245-9.
6. Chrystyn H. Standard for bioequivalence of inhaled products. Clin Pharmacokinet 1994; 26: 1-6.
7. British Association for Lung Research. Determining equivalence of inhaled medications. Respir Med 1995; 89: 253-61.
8. Ahrens RC. On comparing inhaled beta adrenergic agonists. Ann Allergy 1991; 64: 296-8.
9. Ahrens RC, Hendeles L, Clarke WR, Dockhorn RJ, Hill MR, Vaughan LM, Lux C, Han SH. Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler. A Bioassay Using Methacholine. Am J Respir Crit Care Med 1999; 160: 1238-43.
10. Roux FJ, Grandordy B, Douglas JS. Functional and binding characteristics of long-acting β2-agonists in lung and heart. Am J Respir Crit Care Med 1996; 153: 1489-95.
11. Jenne JW, Shaughnessy TK, Druz WS, Manfredi CJ, Vestal RE. In vivo functional antagonism between isoproterenol and bronchoconstrictants in dog. J Appl Physiol 1987; 63: 812-9.
12. Ahrens RC, Harris JB, Milavetz G, Annis L, Ries R. Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in patients with asthma. J Allergy Clin Immunol 1987; 79: 876-82.
13. Parameswaran KN, Inman MD, Ekholm BP, Morris MM, Summers E, O'Byrne PM, Hargreave FE. Protection against methacholine bronchocosntriction to assess relative potency of inhaled β2-agonist. Am J Respir Crit Care Med 1999; 106: 354-7.
14. Creticos PS, Adams WP, Petty BG, Lewis LD, Singh GJ, Khattignavong AP, Molzon JA, Martinez MN, Lietman PS, Williams RL. A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered-dose inhalers. J Allergy Clin Immunol 2002; 110: 713-20.
15. Hendeles L, Beaty R, Ahrens R, Stevens G, Harman EM. Response to inhaled albuterol during nocturnal asthma. J Allergy Clin Immunol 2004; 113: 1058-62.
16. Elsasser S, Donna E, Demirozu CM, Danta I, Wanner A. Metaproterenol responsiveness after methacholine- and histamine-induced bronchoconstriction. Chest 1996; 110: 617-23.
17. Van den Brink FG. The model of functional interaction. I. Development and first check of a new model of functional synergism and antagonism. Eur J Pharmacol 1973; 22: 270-8.
18. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144: 1202-18.
19. Lavorini F, Geri P, Luperini M, Maluccio NM, Mariani L, Marmai C, Pistolesi M, Fontana GA. Clinical and functional responses to salbutamol inhaled via different devices in asthmatic patients with induced bronchoconstriction. Br J Clin Pharmacol 2004; 58: 512-20.
20. Quanjer PH, Tammeling GJ, Cotes JE, Pederson OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party: standardisation of lung function tests. European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J 1993; 6(Suppl 16): 5-40.
21. McFadden ER Jr, Linden DA. A reduction in maximal mid-expiratory flow rate. A spirographic manifestation of airway disease. Am J Med 1972; 52: 725-37.
22. Olsen CR, Hale FC. A method for interpreting acute response to bronchodilators from the spirogram. Am Rev Respir Dis 1968; 98: 301-2.
23. Beach JR, Young CL, Stenton SC, Avery AJ, Walters EH, Hendrick DJ. A comparison of the speed of action of salmeterol and salbutamol in reversing methacholine-induced bronchoconstriction. Pulm Pharmacol 1992; 5: 133-5.
24. Finney DJ. Statistical methods in biological assay, 3rd edn. London: Charles Griffin & Co, 1978.
25. Stewart BA, Arhens RC, Carrier S, Frosolono M, Han SH, Milavetz G. Demonstration of in vivo bioequivalence of a generic albuterol metered-dose inhaler to Ventolin. Chest 2000; 117: 714-21.
26. Ahrens RC, Teresi ME, Han SH, Donnell D, Vanden Burgt JA, Lux CR. Asthma stability after oral prednisone. A clinical model for comparing inhaled steroid potency. Am J Respir Crit Care Med 2001; 164: 1138-45.
27. Food and Drug Administration. Interim guidance for documentation of in vivo bioequivalence of albuterol aerosols (metered-dose inhalers). Rockville, MD: Division of Bioequivalence, Office of Generic Drugs. Food and Drug Administration, 1994. Publication no. 1-27.
28. Marks GB, Yates DH, Sist M, Ceyhan B, De Campos M, Scott DM, Barnes PJ. Respiratory sensation during bronchial challenge testing with methacholine, sodium metabisulphite, and adenosine monophosphate. Thorax 1996; 51: 793-8.
29. Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999; 13: 988-92.
30. van der Woude HJ, Boorsma M, Bergqvist PB, Winter TH, Aalbers R. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther 2004; 17: 89-95.
31. Heimer D, Shim C, Williams MH Jr. The effect of sequential inhalations of metaproterenol aerosol in asthma. J Allergy Clin Immunol 1980; 66: 75-7.
32. Fishwick D, Bradshaw L, Macdonald C, Beasley R, Gash D, Bengtsson T, Bondesson E, Borgstrom L. Cumulative and singledose design to assess the bronchodilator effects of β2-agonists in individuals with asthma. Am J Respir Crit Care Med 2001; 163: 474-7.
33. Lulling J, Delwiche JP, Prignot J. Evaluation of onset of bronchodilating effect by interruption of the air flow method. Eur J Respir Dis 1980; 61: 108-12.
34. Newton MF, O'Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002; 121: 1042-50.
35. Lipworth BJ. Targets for inhaled treatment. Respir Med 2000; 94: S13-S16.
36. Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates. Respir Med 2003; 97: 181-7.
37. Prime D, Grant AC, Slater Al, Woodhouse RN. A critical comparison of the dose delivery characteristics of four alternative inhalation devices delivering salbutamol. pressurized metered-dose inhaler, Diskus inhaler, Diskaler inhaler and Turbuhaler inhaler. J Aerosol Med 1999; 12: 75-84.
38. Stãnescu D. Small airways obstruction syndrome. Chest 1999; 116: 231-3.
39. McFadden ER Jr, Kiser R, DeGroot WJ. Acute bronchial asthma. Relations between clinical and physiological manifestation. N Engl J Med 1973; 288: 221-5.
40. Evans DJ, Green M. Small airways: a time to revisit? Thorax 1998; 53: 629-30.
41. O'Byrne PM, Dolovich J, Hargreave FE. The late asthmatic response. Am Rev Respir Dis 1987; 136: 741-51.